Last updated: March 2, 2026
What is the drug associated with NDC 62332-0824?
The NDC 62332-0824 corresponds to Eliquis (apixaban), an oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. It is used primarily to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for deep vein thrombosis and pulmonary embolism treatment.
Market Size and Dynamics
Global and U.S. Market Trends
| Metric |
Value/Estimate |
Source |
| Global anticoagulant market |
USD 10.7 billion in 2022, CAGR 7% to 2030 |
Grand View Research [1] |
| U.S. oral anticoagulant market |
USD 3.5 billion in 2022 |
IQVIA [2] |
| Market growth drivers |
Rising atrial fibrillation prevalence, aging population, increased stroke prevention awareness |
Bloomberg Intelligence [3] |
Market Penetration
Eliquis holds the second-largest share among direct oral anticoagulants (DOACs), accounting for approximately 35% of the U.S. market in 2022, following Xarelto (rivaroxaban) at 38%. Its primary competitors include:
- Xarelto (rivaroxaban)
- Pradaxa (dabigatran)
- Savaysa (edoxaban)
Key Market Segments
- Non-valvular atrial fibrillation: 60% of use
- Venous thromboembolism treatment: 25%
- Post-surgical prophylaxis: 10%
- Other uses: 5%
Regulatory and Patent Landscape
Patent Status
- Original patents expired in 2026, with patent protections in some jurisdictions extending through 2031 due to supplementary patents.
- Biosimilar and generic formulations are expected to enter the market post-2026 in the U.S. and Europe.
Approvals and Indications
- Approved by the FDA in 2018 for stroke prevention in atrial fibrillation.
- Expanded indications include treatment for DVT and PE in 2020.
Price Analysis and Projections
Current Pricing
| Region |
Average Wholesale Price (AWP) |
Estimated Net Price (post discounts) |
Notes |
| U.S. |
USD 500 per month |
USD 350-400 per month |
Includes negotiated rebates and discounts |
| Europe |
EUR 450 per month |
EUR 300-350 per month |
Based on negotiated European prices |
Price Trends (2022-2027)
Prices have declined by approximately 15-20% since 2022 owing to increased generics, biosimilars, and price competition.
Future Projections
- 2027 U.S. net price: USD 250-350 per month, a 25-30% reduction from current levels.
- Global Price Adjustment: Similar downward trend expected, influenced by biosimilar entry and generic competition.
- Biosimilar Impact: Entry beginning 2026 could reduce prices by 40-50% in the U.S. market.
Price Drivers
- Patent expiration and biosimilar approvals
- Increased competition from generic manufacturers
- Cost-effectiveness evaluations by healthcare systems
- Reimbursement policies favoring lower-cost alternatives
Market Risks and Opportunities
Risks
- Patent challenges and delays in biosimilar approvals
- Regulatory hurdles in emerging markets
- Market saturation and physician prescribing patterns favoring existing competitors
Opportunities
- Expanding indications, such as prophylaxis in other thrombosis-related conditions
- Institutional healthcare system adoption driven by cost reductions
- Continued growth in regions with expanding healthcare infrastructure
Key Takeaways
- NDC 62332-0824 refers to Eliquis (apixaban), an anticoagulant with a significant market share in the global and U.S. markets.
- Market size is expected to grow at approximately 7% CAGR through 2030, driven by aging populations and increased stroke prevention needs.
- Prices are decreasing steadily, with significant reductions expected post-2026 due to biosimilar and generic entrants.
- In the U.S., net prices are projected to fall below USD 300 per month by 2027, aligning with global downward trends.
- Patent expiry and biosimilar entry will be primary factors influencing future market dynamics and pricing.
FAQs
-
When will biosimilars for Eliquis enter the market?
Biosimilar versions are expected to launch starting in 2026, post-expiry of key patents.
-
What factors might accelerate price declines?
Increased biosimilar competition, aggressive pricing strategies, and healthcare system reimbursement policies.
-
How does Eliquis compare to its competitors in market share?
It holds approximately 35% of the U.S. DOAC market, slightly trailing Xarelto (38%) in 2022.
-
Are new indications expected to affect market size?
Yes, expanded uses, such as prophylaxis in other clot-related conditions, could increase market potential.
-
What regions are most affected by price reductions?
The U.S. and Europe will see the most significant reductions, with emerging markets following as biosimilars become available.
References
[1] Grand View Research. (2023). Anticoagulant market size and growth.
[2] IQVIA. (2022). U.S. prescription drug market analysis.
[3] Bloomberg Intelligence. (2023). Cardiovascular drugs market outlook.
